In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abgenix sells $75mm in common stock private placement

Executive Summary

Abgenix Inc., a biotech focused on antibody-based therapeutics, has sold 1.8mm common shares at $42 each in a private placement to institutional and other private investors, bringing in a total of $75.6mm. The shares were sold at about an (pr)11% discount to the average $47.20 market price.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies